Found 13 matching trials
Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers PHASE1 Obtain interaction data between BI 201335 and Efavirenz to guide dosing for...
Show More Location
1220.20.41001 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions PHASE1 The objective of the current study is to investigate the relative bioavaila...
Show More Location
1220.46.1 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C PHASE2 The objective of this trial is to investigate tolerability, safety, pharmac...
Show More Location
1241.25.002 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients PHASE2 The current Standard of Care (SOC) for chronic HCV infection, which is pegy...
Show More Location
1220.14.003 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial PHASE3 The aim of this trial is to evaluate the safety and efficacy of BI 201335 g...
Show More Location
1220.54.08104 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects PHASE1 The objective of this study was to investigate the safety, tolerability, an...
Show More Location
Multiple Locations
Learn More & Join Trial
A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection PHASE3 The objectives of this study are:
1. To evaluate the efficacy and safety o...
Show More Location
Multiple Locations
Learn More & Join Trial
Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers PHASE1 The objective of this study was to establish the relative bioavailability o...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection PHASE2 The substances BI 201335 and BI 207127 are being developed for the treatmen...
Show More Location
1241.21.0003 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects PHASE1 To demonstrate that BI 201335 does not prolong the QT interval more than pl...
Show More Location
Multiple Locations
Learn More & Join Trial